Oracle Buys goBalto

Adds Leading Solution for Accelerating Clinical Trial Site Selection and Activation to Oracle Health Sciences Cloud

News provided by

Oct 17, 2018, 08:09 ET

REDWOOD SHORES, Calif., Oct. 17, 2018 /PRNewswire/ -- Oracle today announced that it has entered into an agreement to acquire goBalto, which delivers leading cloud solutions to accelerate clinical trials by streamlining and automating the selection and set up of the best performing clinical research sites to conduct trials.

goBalto's study startup solutions are activated at over 90,000 research sites across 2,000+ studies in over 80 countries to deliver significant savings to customers with over 30 percent quantifiable reduction in study startup cycle times.

Today, Oracle Health Sciences offers customers the industry's most advanced cloud solution for clinical trial planning, data collection, trial execution and safety management. goBalto adds the leading industry cloud solution that significantly reduces clinical trial startup time. Together, Oracle and goBalto will provide the most complete end-to-end cloud platform dedicated to unifying action and accelerating results for the Life Sciences industry.

"Clinical trial site selection and activation is one of the most manual and time-consuming processes for our customers," said Steve Rosenberg, Senior Vice President and General Manager of Oracle Health Sciences Global Business Unit. "Oracle Health Sciences is designed to provide the industry with the best end-to-end clinical trial experience and the addition of goBalto will further allow our customers to remove another barrier from delivering treatments to patients faster."

"We set out on a mission to streamline the clinical trial study startup process ten years ago because we saw how untenable it was for pharmaceutical companies and contract research organizations to track 1,000+ sites by 1,000+ specialists on spreadsheets," said Jae Chung, Founder and President of goBalto.

"We are delighted to join forces with Oracle as the benefits offered to both our customers and employees as a broader clinical trial continuum are unparalleled in the industry," said Sujay Jadhav, CEO of goBalto.

More information about this announcement is available at www.oracle.com/gobalto.

About Oracle

The Oracle Cloud offers complete SaaS application suites for ERP, HCM and CX, plus best-in-class database Platform as a Service (PaaS) and Infrastructure as a Service (IaaS) from data centers throughout the Americas, Europe and Asia. For more information about Oracle (NYSE:ORCL), please visit us at oracle.com.

Trademarks

Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Oracle is currently reviewing the existing goBalto product roadmap and will be providing guidance to customers in accordance with Oracle's standard product communication policies. Any resulting features and timing of release of such features as determined by Oracle's review of goBalto's product roadmap are at the sole discretion of Oracle. All product roadmap information, whether communicated by goBalto or by Oracle, does not represent a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. It is intended for information purposes only, and may not be incorporated into any contract.

Cautionary Statement Regarding Forward-Looking Statements
This document contains certain forward-looking statements about Oracle and goBalto, including statements that involve risks and uncertainties concerning Oracle's proposed acquisition of goBalto, anticipated customer benefits and general business outlook. When used in this document, the words "anticipates", "can", "will", "look forward to", "expected" and similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Oracle or goBalto, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this document due to a number of risks and uncertainties. Potential risks and uncertainties include, among others, the possibility that the transaction will not close or that the closing may be delayed, the anticipated synergies of the combined companies may not be achieved after closing, the combined operations may not be successfully integrated in a timely manner, if at all, general economic conditions in regions in which either company does business may deteriorate and/or Oracle or goBalto may be adversely affected by other economic, business, and/or competitive factors. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Oracle or goBalto. You are cautioned to not place undue reliance on forward-looking statements, which speak only as of the date of this document. Neither Oracle nor goBalto is under any duty to update any of the information in this document.

SOURCE Oracle